RenovaCare Appoints Dr. Lydia M. Evans to Its Board of Directors and Increases Board Membership – GlobeNewswire

August 04, 2020 08:30 ET | Source: RenovaCare, Inc.

photo-release

Dr. Lydia M. Evans, Director, RenovaCare, Inc.

ROSELAND, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR;www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced the appointment of Lydia M. Evans, M.D. to its Board of Directors. A noted dermatologist, oncologist, and doctor of internal medicine, Dr. Evans has held numerous academic, private, and commercial appointments, and brings extensive insights into the science, technology, and market positioning of wound and skin regeneration therapies.

As RenovaCare continues to advance our portfolio of regenerative technologies, strategic leadership from our Board is increasingly critical as we look to regulatory approval and commercialization. Dr. Evans knowledge and experience will be a strong addition to our Board at such an important time as the Company continues to pursue bringing first-in-class regenerative therapies to market, stated Alan L. Rubino, RenovaCare CEO & President.

"Im pleased to join the RenovaCare Board of Directors at a time of growing demand for modern therapies that promise natural regeneration for burns, wounds, skin disorders and cosmetic imperfections. The RenovaCare CellMist and SkinGun represent an impressive therapeutic approach that replaces painful and complex skin grafting procedures with a gentle mist of the patients own cells. I look forward to assisting the Company in its development, concluded Dr. Evans.

A Columbia Presbyterian and Memorial Sloan Kettering-educated dermatologist, oncologist and doctor of internal medicine, Dr. Evans specializes in state-of-the-art treatments for aesthetic and medical dermatologic procedures. She is currently an Associate Clinical Attending Physician in the Department of Dermatology at New York Presbyterian Medical Center in New York City, a position which includes significant teaching responsibilities. She is also a Fellow of the American Academy of Dermatology, a Diplomate of the National Board of Medical Examiners, the American Board of Internal Medicine, and the American Board of Dermatology. She is a member of the Leadership Society of the Dermatology Research Foundation and has served as the New York State Chairperson for the Psoriasis Research Foundation. Dr. Evans was Consulting Dermatologist to LOral Paris from 2000 to 2012, spurring new product development in dermatologist-inspired skincare directly to consumers. About RenovaCare RenovaCare, Inc. is developing first-of-its-kind autologous (self-donated) stem cell therapies for the regeneration of human organs. Its initial product under development targets the bodys largest organ, the skin. The companys flagship technology, the CellMist System, uses its patented SkinGun to spray a liquid suspension of a patients stem cells the CellMist Solution onto wounds.

RenovaCare is developing its CellMist System as a promising new alternative for patients suffering from burns, chronic and acute wounds, and scars. In the US alone, this $45 billion market is greater than the spending on high-blood pressure management, cholesterol treatments, and back pain therapeutics.

RenovaCare products are currently in development. They are not available for sale in the United States. There is no assurance that the Companys planned or filed submissions to the U.S. Food and Drug Administration will be accepted or cleared by the FDA.

For additional information, please call Amit Singh at: 888-398-0202 or visit:https://renovacareinc.com

To receive future press releases via email, please visit:https://renovacareinc.com/investors/register/

Follow us on LinkedIn:https://www.linkedin.com/company/renovacare-inc-/

Follow us on Twitter:https://twitter.com/RenovaCareInc

Follow us on Facebook:https://www.facebook.com/renovacarercar

Social Media Disclaimer Investors and others should note that we announce material financial information to our investors using SEC filings and press releases. We use our website and social media to communicate with our subscribers, shareholders and the public about the company, RenovaCare, Inc. development, and other corporate matters that are in the public domain. At this time, the company will not post information on social media that could be deemed to be material information unless that information was distributed to public distribution channels first.

We encourage investors, the media, and others interested in the company to review the information we post on the companys website and the social media channels listed below:

* This list may be updated from time to time.

Legal Notice Regarding Forward-Looking Statements No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although RenovaCare, Inc. (the Company) believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words may, will, should, could, expect, anticipate, estimate, believe, intend, or project or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: the timing and success of clinical and preclinical studies of product candidates, the potential timing and success of the Companys product programs through their individual product development and regulatory approval processes, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, obsolescence of the Companys technologies, technical problems with the Companys research, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Companys operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Companys ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, and other risks. There can be no assurance that further research and development will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that the Company will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Companys most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission athttp://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Read more:
RenovaCare Appoints Dr. Lydia M. Evans to Its Board of Directors and Increases Board Membership - GlobeNewswire

MediVet Biologics Rebrands as Ardent Animal Health – Benzinga

LEXINGTON, Ky., Aug. 3, 2020 /PRNewswire-PRWeb/ -- Introducing Ardent Animal Health MediVet Biologics rebrands company and positions its platform of innovative products for transformative growth

MediVet Biologics is announcing a new name and a new look for its corporate brand as it relaunches itself as Ardent Animal Health.

In the years since its inception in 2016, the new Ardent Animal Health has developed into a global leader in the areas of veterinary regenerative medicine and oncology solutions for animals. The company's core mission is to develop affordable, innovative treatments for animal cancer and disease while supporting its veterinary partners in their efforts to make a positive impact on pet health.

"The name 'Ardent' captures the spirit of our organization as a company with fiery passion for innovation guided by compassion for the well-being of animals. The new brand translates the enormous and unique impact our veterinarian customers make each day in the lives of their patients. Our aim is to leverage our brand to accelerate connecting pet owners seeking advanced care to our expanding network of progressive veterinarian partners around the world," says Thomas Masterson, President of Ardent Animal Health.

Under its former brand of MediVet Biologics, Ardent Animal Health developed the first in-clinic adipose regenerative stem cell therapy kit, ActiStem Therapy. A major scientific advancement in animal regenerative medicine, the product offers an economic solution for owners of pets suffering from osteoarthritis, hip dysplasia, and ligament and cartilage injuries, as well as numerous mobility ailments. In addition to regenerative cells from fat, Ardent-certified hospitals offer other biologic treatments such as Platelet Rich Plasma, or PRP, a blood-derived treatment gaining popularity in human sports medicine.

Ardent Animal Health is unique for a company of its size, as it has surrounded its current and pipeline products with strong intellectual property and multiple collaborative university studies. This has allowed the company to grow, cementing its current technology, and look toward the future for its stem cell-based product pipeline candidates. Ardent Animal Health will launch with an extensive following of pet owners and veterinarians positively impacted by its products and services. The studies, passionate customers, and patient outcomes continue to provide momentum for the company's technology and products. Over 20,000 veterinary patients have received treatment of an Ardent Animal Health regenerative product or service.

Ardent Animal Health has also introduced cutting edge science to fight against canine cancer with its cancer vaccine service, K9- ACV, an immunotherapy vaccine generated from a canine patient's own cancerous tumor. K9-ACV is designed to stimulate the canine patient's immune response to attack the cancer. "We are looking to meet an unmet need in pet cancer, at the family veterinarian office when needed. 50% of dogs over the age of ten will develop some type of cancer, so there is a need for a broadly applicable approach that can improve lifespan at a reasonable cost. Our preliminary studies and extensive market research indicate this approach will provide access to pets that need it," Masterson said.

According to Mr. Masterson, the company's strength in these core innovative therapeutic areas will allow the organization to accelerate growth following its recent transition in both leadership and ownership. As a portfolio company of STUCK Fund 1, based in Milwaukee, WI, Ardent Animal Health will continue to develop novel approaches for early disease detection and treatments, with a focus on precision medicine for pets in need.

"We will continue to focus much of our strategy in creating novel products and services utilized in veterinary hospitals. We believe that this approach is key to the future of animal health. It is important not only for value creation but to ensure veterinarians have the ability to diagnose and treat their patients with the same leading-edge strategies underway in human health. Our animal family members deserve it."

Disclaimer Experimental Cancer Vaccines created by Ardent Animal Health are provided under 9 CFR 103.3 via USDA Center for Veterinary Biologics oversight for use under supervision/prescription of a licensed veterinarian. Safety & efficacy have not been yet established.

About Ardent Animal Health

Since 2016 Ardent Animal Health based near Lexington, KY, has provided advanced medical strategies to veterinary hospitals around the world. Ardent provides regenerative medicine treatments such as ActiStem Therapy and PureVet PRP to veterinarians for pain and disease in companion and equine patients. Additionally, Ardent Animal Health is pursuing advanced strategies for detection and treatment of canine cancer. Through creation of its own intellectual property and strategic licensing partners, the company's portfolio includes current and future offerings aimed to raise the standard for animal healthcare.

Home

About STUCK Fund 1

Ardent Animal Health represents an innovation-focused element of the STUCK Fund 1 portfolio, as Ardent competes in the fast-growing and recession-resistant pet health sector. STUCK Fund 1, based in Milwaukee, WI, was founded in 2014 to live out the lessons the investment firm's founders learned from growing its business into an international, $100 million organization. STUCK founders were honored with numerous accolades in their prior ventures, including the Muskego Manufacturing Business of the Year award and the Waukesha Business Alliance Manufacturing Business of the Year honor, among several others. Currently, the investment firm supports like-minded entrepreneurs to accelerate and sustain the growth of their businesses.

About

Media Contact: Matt Yeich (859)885-7111 matt@ardentanimalhealth.com

SOURCE Ardent Animal Health

See the original post:
MediVet Biologics Rebrands as Ardent Animal Health - Benzinga

Church Point Police Captain dies from COVID-19 complications: ‘Go and protect the heavens, my dearest friend’ – The Advocate

A Church Point Police Department captain has died from serious medical complications after contracting COVID-19.

Church Point Police Chief Dale Thibodeaux shared news of Capt. Kevin Trahans death in a post from the departments Facebook page Saturday morning. Thibodeaux wrote that Trahan returned to the job in April after a period of absence to receive a bone marrow or stem cell transplant at MD Anderson Cancer Center in Houston to ward off an unspecified cancer.

He later contracted the virus while on the job, the chief said.

Success! An email has been sent with a link to confirm list signup.

Error! There was an error processing your request.

In a July 22 post on his personal Facebook, Thibodeaux said that the department and Trahans family were asking for prayers while Trahan was hospitalized in the intensive care unit. After being diagnosed with COVID-19, Trahan also suffered from pneumonia, clots in both legs and suffered strokes while sedated on a ventilator, the chief relayed from Trahans son.

Trahan died around 10:30 p.m. Friday at a Monroe hospital and Church Point police officers will be escorting his body back to Acadia Parish Saturday, Thibodeaux said.

Trahan, 59, leaves behind his wife, Brenda, who also works for the Church Point Police Department, three adult children, two stepdaughters, two grandchildren and a step-granddaughter, Thibodeaux said.

He tried to help everyone and would give you the shirt off his back if he could. Capt. Trahan was also a dedicated officer and always gave a hundred percent all the timeWith all Capt. Trahan fought through and continued to do his job on a professional level, he was and always will be a true hero, Thibodeaux wrote.

Go and protect the heavens, my dearest friend, family and my brother. The Lord needs you right now more than we do, I guess. You will be missed dearly.

Trahan served in law enforcement for roughly 30 years as a deputy with the Acadia Parish Sheriffs Office and an officer with the Church Point Police Department, the chief said. When Thibodeaux assumed the chief position, Trahan became his right hand man.

While close from their time in law enforcement, the two men were more than brothers in blue they were also family. Trahan was married to Thibodeauxs sister-in-law, he said.

Trahan was generous, kind, determined, hardworking and had a way of talking to people that reached them, Thibodeaux said. He was passionate about helping people and serving the community; even after his treatment at MD Anderson, it was impossible to keep him assigned to desk duty because he was determined to give his best effort on patrol, the chief said.

Everyone who knew him liked him.

His personality was something else. Theres no way he didnt walk into a room and liven it up in some kind of way, Thibodeaux said.

Other law enforcement officers shared condolences online and remembered Trahans commitment to serving the community and mentoring other officers.

It was an honor to know and learn from such a great man. Captain Kevin Trahan was genuinely a good guy who was beyond willing to teach and show beginning officers the way to become a good officer. In the two years I've been with the police department I have gotten to ride and sit with him many times and just simply listen to his stories and learn many things. He will definitely be missed, Church Point Police Officer Holden Hare shared on Facebook.

I received some of the best advice from you when I started this career and I will forever hold on to that advice and guidance youve given me. May you finally Rest In Peace as your legacy will never be forgotten, Hunter Hare wrote.

See original here:
Church Point Police Captain dies from COVID-19 complications: 'Go and protect the heavens, my dearest friend' - The Advocate

BMT survivor study finds significant breast cancer risk in young women who received total body irradiation – The Mix

Women who had total body irradiation to prepare for blood or marrow transplantation before age 30 had a 4.5-fold increase in their risk of developing breast cancer later in life.

Smita Bhatia, M.D.A new study examining long-term outcomes of blood or marrow transplantation (BMT) found that patients who received total body irradiation (TBI) at age 30 or younger had a 4.5-fold increase in their risk of developing breast cancer later in life compared with the general population. The research, published in the Journal of Clinical Oncology on July 16, 2020, also found increased risk of breast cancer among women exposed to alkylating agents and anthracyclines as part of BMT.

Women who received TBI were at a 1.5-fold higher risk of breast cancer when compared with the general population overall and at a 4.5-fold higher risk when the exposure occurred at age 30 years or younger, the authors write. Women who were exposed to TBI before age 30 had a 13.9 percent risk of being diagnosed with breast cancer by age 50, they found. By comparison, the average American woman has a 2.38 percent risk of being diagnosed with breast cancer at age 50, according to the American Cancer Society.

As a result of this study, we will be recommending that those transplanted at ages less than 30 years with TBI receive screening with mammography and breast MRI for early detection of breast cancer, said Smita Bhatia, M.D., senior author of the study and director of the Institute for Cancer Outcomes and Survivorship and a senior scientist in the ONeal Comprehensive Cancer Center at the University of Alabama at Birmingham.

"We plan to further study how different aspects of TBI dose and delivery technique are related to secondary cancers, said Andrew McDonald, M.D., assistant professor in the Department of Radiation Oncology and first author of the study. Our long-term goal is to improvetreatment techniques for future patients undergoing BMT as part of their cancer care."

This research was based on the BMT Survivor Study, which is enrolling more than 10,000 patients from the UAB, City of Hope and the University of Minnesota medical centers who underwent transplantation between 1974 and 2014 and survived for at least two years. Survival rates after BMT have been improving at the rate of 10 percent per decade, Bhatia said. But these BMT survivors are uniquely vulnerable to long-term health problems, she said.

Some 23,000 patients received BMT in the United States in 2018, according to the latest figures from the Center for International Blood & Marrow Transplant Research. These are mainly patients with blood cancers such as leukemia, myeloma or lymphoma that are progressing or who have a high risk of relapse. Total body irradiation and chemotherapeutic exposures such as alkylating agents and anthracyclines are used to prepare the patient for BMT.

About 50 percent of [BMT] transplant patients overall receive total body irradiation, including a higher proportion of those patients who are younger, Bhatia said. The decision whether or not to use TBI as part of BMT is based on the primary cancer that is being treated and the type of transplant that is performed, she noted. TBI is used more often among those who receive transplants from their siblings or unrelated donors known as allogeneic transplant as compared to when they receive transplants from their own stem cells, known as autologous transplant.

Bhatias institute is particularly interested in identifying predictive traits of cancer survivors at higher risk for long-term problems that could enable health care providers to tailor screenings and other interventions to these populations.

One under-studied outcome in BMT survivors is the magnitude of risk of breast cancer among women treated with TBI across all ages, Bhatia said. Early detection is known to improve breast-cancer outcomes and data on the women at highest risk to develop radiation-related breast cancer would allow health providers to screen these women at earlier ages.

Women who had a history of breast cancer before BMT, chest radiation before BMT or a mastectomy before BMT were not included in the study cohort. The researchers studied a total of 1,464 female BMT survivors 788 who had allogeneic transplants and 676 who had autologous transplants. TBI was used in 46 percent (660) of these patients. The median length of follow-up was 9.3 years. The most common diagnoses were acute myeloid leukemia or myelodysplastic syndrome (27.5 percent), non-Hodgkin lymphoma (23.3 percent), plasma cell dyscrasias (18 percent), and chronic myelogenous leukemia (10.3 percent).

Thirty-seven of the women developed breast cancer during the study period 19 of the women who had allogeneic transplants and 18 who had autologous transplants. The women developed breast cancer at a median of 9.1 years after BMT. Breast cancers, inclusive of ductal carcinoma in situ, were identified from the completed BMTSS survey.

"To our knowledge, this is the first report of an increased risk of subsequent breast cancer after TBI among female autologous BMT survivors, the authors write. The observation that exposure to alkylating agents and anthracyclines is associated with an increased risk of subsequent breast cancer has been noted in long-term outcomes studies of childhood cancer survivors; however, to our knowledge, this is the first report of this association among BMT survivors.

The researchers did not observe a relationship between TBI dose and the risk of subsequent breast cancer in this study, they write. But the distribution of TBI doses used for the women included in this study was narrow, and additional research is needed to determine if a dose-response relationship between TBI and subsequent breast cancer exists.

In addition to McDonald and Bhatia, other authors of Total Body Irradiation and Risk of Breast Cancer After Blood or Marrow Transplantation: A Blood or Marrow Transplantation Survivor Study Report, include Yanjun Chen, Jessica Wu, Lindsey Hageman, Liton Francisco, Michelle Kung, Emily Ness, Wendy Landier, Ph.D., Kevin Battles, and Donna Salzman, M.D., of UAB; F. Lennie Wong, Ph.D., Saro H. Armenian, D.O., and Stephen J. Forman, M.D., of City of Hope; and Daniel J. Weisdorf, M.D., and Mukta Arora, M.D., of the University of Minnesota.

The work was supported in part by grants from the National Cancer Institute (R01 CA078938 and U01 CA213140) and the Leukemia Lymphoma Society (R650216).

See original here:
BMT survivor study finds significant breast cancer risk in young women who received total body irradiation - The Mix

Hyperbaric Oxygen Therapy Can Enhance Cognition in Healthy Older Adults – PsychCentral.com

A new Israeli study finds that a new hyperbaric oxygen therapy protocol can improve cognitive function in older adults.

The main areas of improvement were attention, information processing speed, and executive function, in addition to global cognitive function. All of these typically decline with age, according to researchers at the Shamir Medical Center and the Sackler School of Medicine and Sagol School of Neuroscience at Tel Aviv University in Israel.

The researchers report there was also a significant correlation between the cognitive changes and improved cerebral blood flow in specific brain locations.

The randomized controlled clinical trial included 63 healthy adults with an average age of 64. According to the researchers, 33 underwent HBOT for three months, while the remaining 30 were the control group.

Cognitive function was measured by a standardized comprehensive battery of computerized cognitive assessments before and after the three months. Cerebral blood flow (CBF) was evaluated by a magnetic resonance imaging technique for brain perfusion.

Age-related cognitive and functional decline has become a significant concern in the Western world. Major research efforts around the world are focused on improving the cognitive performance of the so-called normal aging population, said co-author Dr. Shai Efrati, head of the Sagol Center for Hyperbaric Medicine and Research, and Head of Research & Development at Shamir Medical Center. In our study, for the first time in humans, we have found an effective and safe medical intervention that can address this unwanted consequence of our age-related deterioration.

Years of research led to an advanced understanding of HBOTs ability to restore brain function, added co-author Dr. Amir Hadanny of the Sagol Center.

Efrati and Hadanny designed the study based on a hyperbaric oxygen therapy (HBOT) protocol developed at the Sagol Center over the past 10 years.

In the past, we have demonstrated HBOTs potential to improve/treat brain injuries such as stroke, traumatic brain injury, and anoxic brain injury due to sustained lack of oxygen supply by increasing brain blood flow and metabolism, Hadanny said. This landmark research could have a far-reaching impact on the way we view the aging process and the ability to treat its symptoms.

During HBOT, the patient breaths in pure oxygen in a pressurized chamber where the air pressure is increased to twice that of normal air. This process increases oxygen solubility in the blood that travels throughout the body, the researchers explained. The added oxygen stimulates the release of growth factors and stem cells, which promote healing. HBOT has been applied worldwide mostly to treat chronic non-healing wounds, the researchers noted.

There is a growing body of evidence on the regenerative effects of HBOT, they add. The researchers demonstrated that the combined action of delivering high levels of oxygen (hyperoxia) and pressure (hyperbaric environment) leads to significant improvement in tissue oxygenation while targeting both oxygen and pressure sensitive genes, resulting in restored and enhanced tissue metabolism. These targeted genes induce stem cell proliferation, reduce inflammation, and induce the generation of new blood vessels and tissue repair mechanisms, according to the researchers.

The occlusion of small blood vessels, similar to the occlusions which may develop in the pipes of an aging home, is a dominant element in the human aging process. This led us to speculate that HBOT may affect brain performance of the aging population, Efrati said.

We found that HBOT induced a significant increase in brain blood flow, which correlated with cognitive improvement, confirming our theory. One can conjecture that similar beneficial effect of HBOT can be induced in other organs of the aging body. These will be investigated in our upcoming research.

The study was published in the peer-reviewed journal Aging.

Source: American Friends of Tel Aviv

APA Reference Wood, J. (2020). Hyperbaric Oxygen Therapy Can Enhance Cognition in Healthy Older Adults. Psych Central. Retrieved on July 29, 2020, from https://psychcentral.com/news/2020/07/27/hyperbaric-oxygen-therapy-can-enhance-cognition-in-healthy-older-adults/158208.html

Read the rest here:
Hyperbaric Oxygen Therapy Can Enhance Cognition in Healthy Older Adults - PsychCentral.com

The surprising recovery with stem cells of 26 COVID-19 patient in Hidalgo – Explica

The treatment was applied to patients suffering from Acute Respiratory Distress Syndrome due to COVID-19. (Photo: . / Edgard Garrido)

The Governor of the State of Hidalgo, Omar Fayad Meneses, announced that through the use of mesenchymal stem cells and exosomes, 26 Hidalguenses who were severe with COVID-19 managed to recover.

This as part of a study carried out by the state government in collaboration with that of Japan, according to the newspaper El Universal. Thirty patients participated in the project, who received an innovative biotechnological therapy to treat COVID-19. They were all in serious condition, but 26 of them managed to recover as a result of the treatment.

The agreement to carry out these activities was agreed on June 13 at a meeting between the Hidalgo administration and the International Association of Cell Therapy for the New Coronavrius (IACT4C).

In presenting the results, the Governor thanked the doctor Tetsuya Fujimori and the researchers, Alex Iryiz and Sergio Alva for having been part of the project.

He assured that based on these promising results, we will seek approval in Hidalgo for this revolutionary treatment for COVID-19. In the same direction, it was reported that an authorization would be requested to make a stem cell processing center that will have a high-level technology called Prometheus.

Mexico has positioned itself in fifth place in Latin America and 13th worldwide. (Photo: . / Edgard Garrido)

Currently, the study is in its second phase, in which it is controlled and analyzes the safety and efficacy of the use of exosomes and human mesenchymal cells intravenously applied.

The Mexican media reported that the treatment was applied to patients who suffered Acute Respiratory Distress Syndrome because of COVID-19.

The president reiterated his willingness to continue collaborating with the Japanese government and that a positive aspect of the crisis is that closer ties between countries so far away are achieved.

The governor also used his Twitter account to report that to date there are 6,467 confirmed cases of COVID-19, in addition to 1,003 deaths. There are also 1,282 recovered cases and 1,282 recovered patients.

These are part of the 44,876 deaths and 402,876 confirmed cases accumulated nationwide until the 58th day of the so-called new normality. Likewise, 449,854 negative cases, 87,538 suspects and 261,457 recovered patients have been counted.

To address the pandemic, the government received on July 28, 20 ventilators for intensive care. The Ministry of Foreign Affairs (SRE) explained that the arrival of the fans was the result of cooperation between the governments of Mexico and the United States and of the conversation between the presidents. Andrs Manuel Lpez Obrador and Donald Trump on April 17, where the acquisition of equipment from that country was agreed.

The Governor thanked Dr. Tetsuya Fujimori and the researchers, Alex Iryiz and Sergio Alva for having been part of the project. (Photo: . / Edgard Garrido)

During the morning conference, the Undersecretary for Prevention and Health Promotion, Hugo Lpez-Gatell, He pointed out that in 20 states the infections of coronavirus increase day by day, however in 12 they go down.

In the mortality ranking, Mexico has positioned itself in fifth place in Latin America and 13th worldwide. About73% of deaths were associated with at least one comorbidity, mainly hypertension, diabetes and obesity.

Actually, Mexico City continues to be the entity with the highest number of active casesfollowed by Guanajuato, Nuevo Len, which rose by one place, Estado de Mxico, Veracruz, which rose by two places, Tabasco, Coahuila, which rose by one site, Jalisco, Yucatan, rose by one place, and Puebla.

MORE ABOUT THIS TOPIC:

Coronavirus in Mexico: the country exceeded 400,000 infections

20 new fans arrived in Mexico from the US

Fatigue, shortness of breath, pain: the 17 symptoms that persist after passing COVID-19

Coronavirus in Mexico: 777 people have taken refuge due to lack of government support

July 29, 2020

Read more here:
The surprising recovery with stem cells of 26 COVID-19 patient in Hidalgo - Explica

Johnny Tabaie is proud to announce the most powerful Stem Cell Therapy – Press Release – Digital Journal

Johnny The Healer aka Johnny Tabaie is proud to announce the most powerful Stem Cell Therapy. This is our newest addition to an already very powerful treatment method. Offering the most innovative holistic natural approach to healing the mind the body to soul.

Johnny Tabaie aka Johnny The Healer created The Holistic Sanctuary 10 years ago, he has taken by storm the holistic health movement by creating and pioneering this new paradigm of healing.

Treatments like Massage therapy, Reiki sessions, Kundalini Yoga, HBOT hyperbaric oxygen therapy chamber sessions, daily iv drips NAD+, Amino drips, O-Zone infusion therapy, Ayahuasca ceremonies, Ibogaine treatment, DMT sessions, Stem Cell treatment, holistic dentistry and much more.

The unique and carefully weaved holistic modalities create the most effective and innovative therapy protocols ever created to date. With 80% success rate, patients are not prescribed addictive or toxic medications, or undergo countless hours of talk therapy group therapy and psychobabble instead they are they receive 150 hours of holistic one on one in a four-week inpatient program.

Patients who suffer from depression, PTSD, anxiety, drug addiction, alcohol addiction, medication dependency all enroll to experience this life changing healing method.

The five-star reviews all over the Internet showcases to success, effectiveness and healing potential of Johnny Tabaies healing center.

Media Contact Company Name: Johnny The Healer Contact Person: Johnny Tabaie Email: Send Email Phone: +1-310-601-7805 City: Los Angeles State: CA Country: United States Website: http://www.johnnythehealer.com/

See the rest here:
Johnny Tabaie is proud to announce the most powerful Stem Cell Therapy - Press Release - Digital Journal

COVID-19 Fibroblast Based Cell Therapy Candidate Shown to Reduce Lung Scarring in Aggressive Animal Model – El Paso Inc.

HOUSTON, July 21, 2020 /PRNewswire/ --FibroGenesis announced today new data supporting use of its PneumoBlast product in the battle against COVID-19.Using the widely accepted bleomycin model of lung scarring (fibrosis), Company scientists have demonstrated the administration and use of PneumoBlast induced a 51% reduction of lung fibrosis,which was statistically significant (p < .005). Importantly, when PneumoBlast was compared head to head with bone marrow derived mesenchymal stem cells (BMSCs) for COVID-19, PneumoBlast was 221% more effective. In producing the potent anti-inflammatory protein interleukin 1 receptor antagonist, which is believed to be the mechanism of scar tissue prevention by BMSC therapies currently in development, PneumoBlast was 192% more effective than BMSCs which was again, statistically significant(p < .005).

During an interview with Healthline.com, Dr. Lori Shah, transplant pulmonologist at New York-Presbyterian/Columbia University Irving Medical Center, stated "Holes in the lungs likely refers to an entity that has been dubbed 'post-COVID fibrosis,' otherwise known as post-ARDS [acute respiratory distress syndrome] fibrosis, which is irreversible and can result in severe functional limitations from patients, such as cough, shortness of breath, and need for oxygen." It has been reported that pulmonary fibrosis due to COVID-19 is occurring in increasing numbers of patients in their 20s and 30s.

"COVID-19 represents a new clinical entity which not only causes death through lung inflammation, but in some patients causes permanent lung injury through stimulation of scarring," said Tom Ichim, Ph.D., Chief Scientific Officer of FibroGenesis. "The prospects that our cell therapy approach not only possesses therapeutic effects on animal models of the acute stage of COVID-19, but also benefits the long-term pathology, has our research team extremely excited."

"As the scientific and medical community is discovering more about the biological and medical consequences of the COVID-19 infection, FibroGenesis is eager to contribute to the therapeutic cure options currently being created to fight this global war against an invisible enemy," commented Pete O'Heeron, President/CEO of FibroGenesis. "While we are excited about potential vaccines in the pipeline, the fact remains that there are 3.8 million confirmed cases of COVID-19 in the U.S. and we do not know what the long-term outcomes for these patients will be. To our knowledge, we are the only cell therapy company which is creating a therapy to resolve the initial pathology of infection and also proactively tackling its long-term consequences."

About FibroGenesis

Based in Houston, Texas, FibroGenesis, is a regenerative medicine company developing an innovative solution for chronic disease treatment using human dermal fibroblasts. Currently, FibroGenesis holds 235+ U.S. and international issued patents/patents pending across a variety of clinical pathways, including Disc Degeneration, Multiple Sclerosis, Parkinson's, Chronic Traumatic Encephalopathy, Cancer, Diabetes, Liver Failure, Colitis and Heart Failure. Funded entirely by angel investors, FibroGenesis represents the next generation of medical advancement in cell therapy.

Visit http://www.Fibro-Genesis.com.

Follow this link:
COVID-19 Fibroblast Based Cell Therapy Candidate Shown to Reduce Lung Scarring in Aggressive Animal Model - El Paso Inc.

‘Self-eating’ process of stem cells may be the key to new regenerative therapies – 7thSpace Interactive

'Self-eating' process of stem cells may be the key to new regenerative therapies

PHILADELPHIA--The self-eating process in embryonic stem cells known as chaperone-mediated autophagy (CMA) and a related metabolite may serve as promising new therapeutic targets to repair or regenerate damaged cells and organs, Penn Medicine researchers show in a new study published online in Science.

Human bodies contain over 200 different types of specialized cells. All of them can be derived from embryonic stem (ES) cells, which relentlessly self-renew while retaining the ability to differentiate into any cell type in adult animals, a state known as pluripotency. Researchers have known that the cells' metabolism plays a role in this process; however, it wasn't clear exactly how the cells' internal wiring works to keep that state and ultimately decide stem cell fate.

The new preclinical study, for the first time, shows how the stem cells keeps CMA at low levels to promote that self-renewal, and when the stem cell is ready, it switches that suppression off to enhance CMA, among other activities, and differentiate into specialized cells.

"It's an intriguing discovery in the field of stem cell biology and for researchers looking to develop therapies for tissue or organ regeneration," said senior author Xiaolu Yang, PhD, a professor of Cancer Biology at the Abramson Family Cancer Research Institute in the Perelman School of Medicine at the University of Pennsylvania. "We reveal two novel ways to potentially manipulate the self-renewal and differentiation of stem cells: CMA and a metabolite, known as alpha-ketoglutarate, that is regulated by CMA. Rationally intervening or guiding these functions could be a powerful way to increase the efficiency of regenerative medicine approaches."

Autophagy is a cell-eating mechanism necessary for survival and function of most living organisms. When cells self-eat, the intracellular materials are delivered to lysosomes, which are organelles that help break down these materials. There are a few forms of autophagy. However, unlike the other forms, which are present in all eukaryotic cells, CMA is unique to mammals. To date, the physiological role of CMA remains unclear.

Using metabolomic and genetic laboratory techniques on the embryonic stem cells of mice, the researchers sought to better understand significant changes that took place during their pluripotent state and subsequent differentiation.

They found that CMA activity is kept at a minimum due to two cellular factors critical for pluripotency--Oct4 and Sox2--that suppresses a gene known as LAMP2A, which provides instructions for making a protein called lysosomal associated membrane protein-2 necessary in CMA. The minimal CMA activity allows stem cells to maintain high levels of alpha-ketoglutarate, a metabolite that is crucial to reinforce a cell's pluripotent state, the researchers found.

When it's time for differentiation, the cells begin to upregulate CMA due to the reduction in Oct4 and Sox2. Augmented CMA activity leads to the degradation of key enzymes responsible for the production of alpha-ketoglutarate. This leads to a reduction in alpha-ketoglutarate levels as well as an increases in other cellular activities to promote differentiation. These findings reveal that CMA and alpha-ketoglutarate dictate the fate of embryonic stem cells.

Embryonic stem cells are often called pluripotent due to their remarkable ability to give rise to every cell type in the body, except the placenta and umbilical cord. Embryonic stem cells not only provide a superb system to study early mammalian development, but also hold great promise for regenerative therapies to treat various human disorders. The development of stem-cell based regenerative medicine therapies has rapidly increased in the last decade, with several approaches in studies shown to repair damaged heart tissue, replace cells in solid organ transplantation, and in some cases address neurological disorders.

"This newly discovered role of autophagy in the stem cell is the beginning of further investigations that could lead to researchers and physician-scientists to better therapies to treat various disorders," Yang said.

###

Penn co-authors of the study include the first author Yi Xu, a post-doctoral researcher in Yang's Lab, Yang Zhang and Sixiang Yu, also in Yang's lab, Lili Guo and Ian A. Blair of the department of Systems Pharmacology and Translational Therapeutics, Mengyuan Kan of the department of Biostatistics, Epidemiology and Informatics, as well as Juan C. Garca-Caaveras and Joshua D. Rabinowitz of Princeton University.

The study was supported the National Institutes of Health (R01CA182675, R01CA184867, R01CA235760, and P30ES013508, and the Department of Defense (W81XWH-15-1-0678).

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $7.8 billion enterprise.

The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $425 million awarded in the 2018 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center--which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report--Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation's first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Home Care and Hospice Services, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.

Penn Medicine is powered by a talented and dedicated workforce of more than 40,000 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2018, Penn Medicine provided more than $525 million to benefit our community.

This story has been published on: 2020-07-23. To contact the author, please use the contact details within the article.

Read more from the original source:
'Self-eating' process of stem cells may be the key to new regenerative therapies - 7thSpace Interactive

R3 International Now Including Exosomes with Stem Cell Therapy Program for Autism in Mexico – PR Web

Stem Cell and Exosome Therapy for Autism in Mexico (888) 988-0515

SCOTTSDALE, Ariz. (PRWEB) July 23, 2020

R3 International is now including exosomes with its stem cell therapy program in Mexico for autism. They have been shown to be an effective, safe option for autism patients.

Stem cell and exosome therapy for autism has shown excellent outcomes at R3 International in Tijuana, with the procedures performed by licensed, expert doctors. The doses of biologic are calculated based on the patient's weight. Up to 200 million stem cells are included, along with over 100 billion exosomes.

Autism treatment with regenerative biologics has been very safe and each patient (and family) receives an escort from San Diego to the treatment clinic in Mexico. The autism stem cell treatment center is only twenty minutes from the San Diego International Airport.

According to R3 CEO David Greene, MD, MBA, "Our autism program includes first rate biologics with cell counts that are very high. Safety is paramount, and the lab's safety standards exceed those of the FDA. We set the program up to be extremely cost effective with several options to make it convenient for patient families!"

There are multiple treatment options for autism patients including: 1. A one time visit with 30 or 50 million stem cells starting at $2975. 2. A 5 day stay with several treatments starting at $8975. 3. Several visits over a year period, all inclusive starting at $10,475.

The exosome part of the therapy includes billions of exosomes and is provided at no additional charge. Exosomes are derived from mesenchymal stem cells, and are amazing at cell to cell communication. Research has shown that exosomes are vital in the development of neural circuits, which can enhance the clinical outcomes for autism (Natl Acad Sci, 2019).

To get started with stem cell and exosome therapy for autism in Mexico, call R3 today at (888) 988-0515.

Share article on social media or email:

More here:
R3 International Now Including Exosomes with Stem Cell Therapy Program for Autism in Mexico - PR Web